Don Charleen G, Smieško Martin
Computational Pharmacy Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Front Pharmacol. 2020 May 13;11:683. doi: 10.3389/fphar.2020.00683. eCollection 2020.
The annual increase in depression worldwide together with an upward trend in the use of alternative medicine as treatment asks for developing reliable safety profiles of herbal based medicine. A considerable risk on adverse reactions exists when herbal remedies are combined with prescription medication. Around 25% of the drugs, including many antidepressants, depend on the activity of CYP2D6 for their metabolism and corresponding efficacy. Therefore, probing CYP2D6 inhibition by the active substances in herbal based medicine within the wild-type enzyme and clinically relevant allelic variants is crucial to avoid toxicity issues. In this study several compounds with herbal origin suggested to have antidepressant activity were analyzed on their CYP2D6 wild-type and inhibition potential using molecular docking. In addition, several pharmacokinetic properties were evaluated to assess their probability to cross the blood brain barrier and subsequently reach sufficient brain bioavailability for the modulation of central nervous system targets as well as characteristics which may hint toward potential safety issues.
全球抑郁症的年发病率呈上升趋势,同时替代医学作为治疗手段的使用也呈上升趋势,这就需要开发基于草药的可靠安全性概况。当草药疗法与处方药联合使用时,存在相当大的不良反应风险。包括许多抗抑郁药在内,约25%的药物依赖CYP2D6的活性进行代谢和相应的疗效。因此,研究基于草药的活性物质对野生型酶和临床相关等位基因变体中CYP2D6的抑制作用对于避免毒性问题至关重要。在本研究中,使用分子对接分析了几种具有抗抑郁活性的草药来源化合物对CYP2D6野生型的抑制潜力。此外,还评估了几种药代动力学性质,以评估它们穿过血脑屏障并随后达到足够的脑生物利用度以调节中枢神经系统靶点的可能性,以及可能暗示潜在安全问题的特征。